Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Addictive potential in man: methodological aspects]

D Warot1, D Marra

  • 1Département de Pharmacologie, Hôpital Pitié-Salpêtrière, Paris, France.

Therapie
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of the first wave of the COVID-19 pandemic on French Health students.

L'Encephale·2022
Same author

Self-rated residual symptoms do not predict 1-year recurrence of depression.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Inflammation and cancer prevention.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same author

Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects.

Fundamental & clinical pharmacology·2004
Same author

Psychological stress and cortisol secretion in anhedonic alcoholic men.

European psychiatry : the journal of the Association of European Psychiatrists·2003
Same author

[Medical-psychiatric units, a concept to be developed].

La Revue de medecine interne·2003
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Clinical studies are essential for assessing drug abuse liability, including tolerance and dependence. Comprehensive methodologies are needed to accurately evaluate drug effects and risks during development.

Area of Science:

  • Pharmacology
  • Clinical Psychology
  • Drug Development

Context:

  • Clinical abuse liability testing is crucial for new drug development.
  • Evaluating tolerance, psychic, and physical dependence requires rigorous clinical studies.
  • Standardized methodologies are essential for accurate drug risk assessment.

Purpose:

  • To review existing clinical methodologies for abuse liability testing.
  • To highlight the need for multidimensional assessment in drug development.
  • To identify areas for improvement in evaluating drug discontinuation symptoms.

Summary:

  • Clinical drug abuse liability testing involves assessing tolerance and dependence through various study designs.
  • Methodologies include double-blind evaluations, dose-response studies, and interruption protocols.

Related Experiment Videos

  • Reinforcing effects are studied via self-administration, choice procedures, questionnaires (ARCI, SDQ), and discrimination tasks.
  • Differentiating rebound, withdrawal, and recurrence requires optimal post-treatment observation scales.
  • Multidimensional assessment is vital for predicting the relative risk of new compounds.

    • Impact:

    • Informs the development of more predictive and reliable methods for clinical abuse liability testing.
    • Contributes to safer drug development by improving the assessment of potential risks.
    • Aids in differentiating between drug withdrawal, rebound, and recurrence phenomena.